Stepholidine (Isoquinoline Alkaloid · D1 Agonist/D2 Antagonist · Schizophrenia Research)
| Compound | Stepholidine (l-SPD) |
| Chemical class | Alkaloid — Isoquinoline (Tetrahydroprotoberberine / Aporphine hybrid) |
| CAS | 3572-07-6 |
| Primary source | Stephania intermedia, Stephania spp. |
| Key applications | Schizophrenia research (D1 agonist/D2 antagonist), neuroprotective |
| Claim strength | Moderate |
| Typical form | Research-grade isolate; specialist Stephania extract |
| Buy from Herbuno | Request availability and bulk pricing → |
Commercial source: Stepholidine (l-SPD) is commercially available as a research-grade chemical from specialist chemical suppliers. Dedicated Stephania alkaloid extracts standardised to stepholidine are not widely available at supplement scale. Contact Herbuno for sourcing availability. Traditional use: Stephania species have traditional use in TCM for rheumatic joint conditions, pain management, and anti-inflammatory applications — typically as part of the Stephania/Han Fang Ji alkaloid complex. Stepholidine is a minor constituent in most Stephania species; tetrandrine and fangchinoline are the dominant Stephania alkaloids. Research trajectory: Stepholidine has attracted significant pharmaceutical research interest as a unique dopamine receptor modulator with the unusual property of being simultaneously a D1 agonist and D2 antagonist — a pharmacological profile not achieved by any currently approved antipsychotic drug. This novel dual mechanism has been explored for schizophrenia management, where D2 antagonism (current antipsychotics) combined with D1 agonism (which may address negative symptoms unaddressed by D2 antagonists alone) represents a theoretical improvement over current antipsychotic pharmacology. See sourcing options below.
Evidence for Stepholidine Applications
Dual D1 agonist/D2 antagonist — schizophrenia research: Stepholidine (l-SPD) simultaneously activates D1 receptors and blocks D2 receptors — a dual mechanism proposed to address both positive and negative symptoms of schizophrenia. In animal schizophrenia models, l-SPD reduces hyperactivity (D2 antagonism), improves working memory deficits (D1 agonism in prefrontal cortex), and reduces stereotyped behaviours. Chinese clinical studies of l-SPD in schizophrenia patients showed antipsychotic efficacy. Claim strength: Moderate (animal + Chinese clinical; not replicated in Western RCTs).
Neuroprotective: Stepholidine protects dopaminergic neurons from MPTP toxicity in Parkinson’s disease models, combining D1 agonism (which is neuroprotective in nigral neurons) with the anti-inflammatory effects documented for the Stephania alkaloid class. Claim strength: Moderate.
Request availability and bulk pricing →
Browse Standardised Extract Powders →
Dosage & Formulator Specification
Stepholidine is not a supplement ingredient. Its primary application is as a research tool compound for dopaminergic receptor pharmacology and as a potential lead compound for pharmaceutical antipsychotic drug development. Formulators should not attempt to position stepholidine as a supplement active for schizophrenia or psychotic conditions — these require pharmaceutical regulatory pathways. For reference, Chinese clinical studies used doses of 30–120 mg/day l-SPD. Contact Herbuno for research-grade material availability.
Frequently Asked Questions — Stepholidine
What makes the D1 agonist/D2 antagonist mechanism unique in antipsychotic pharmacology?
All current approved antipsychotic drugs act primarily as D2 antagonists. D2 antagonism reduces positive symptoms (hallucinations, delusions) but does not address — and may worsen — negative symptoms (flat affect, cognitive deficits, social withdrawal). D1 receptors in the prefrontal cortex are critical for working memory and cognitive function. Stepholidine’s combination of D1 agonism + D2 antagonism theoretically addresses both symptom domains simultaneously — a pharmacological profile sought by schizophrenia pharmacologists for decades.
Why hasn’t stepholidine been developed into a pharmaceutical?
Despite promising pharmacological properties, stepholidine faces challenges including difficult synthesis at scale, unclear bioavailability and metabolic stability data in Western population contexts, and the general difficulty of CNS drug development. Chinese clinical studies provide encouraging but not definitive evidence by international regulatory standards. The compound remains a research lead rather than a developed pharmaceutical.
Is stepholidine related to tetrandrine from Stephania?
Both come from Stephania species but are structurally distinct. Tetrandrine is a bisbenzylisoquinoline alkaloid (two connected benzylisoquinoline units); stepholidine is an aporphine/tetrahydroprotoberberine hybrid (single unit, tetracyclic). Their pharmacological profiles are entirely different: tetrandrine is primarily a calcium channel blocker with anti-inflammatory properties; stepholidine is a dopamine receptor modulator. The Stephania genus contains enormous alkaloid structural diversity.
Can stepholidine be included in any supplement formulation currently?
No regulatory-compliant supplement formulation can make claims related to stepholidine’s antipsychotic mechanism, as these imply treatment of a medical condition (schizophrenia). Stepholidine is appropriately positioned as a research reference compound and a fascinating example of plant-derived alkaloid pharmacology informing pharmaceutical drug discovery.
Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.
← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery